Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Report includes call to action outlining steps Congress must take to maintain momentum.
New research shows PD-L1 interaction can alter cancer intrinsic signaling in head and neck cancer, among others.
Study results help explain why some cancers have different prognosis in men and women, and also suggest novel treatment strategies.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
Keytruda plus chemotherapy reduced the risk of death by about 40% for people with persistent, recurrent or metastatic cervical cancer.
Checkpoint inhibitor therapies are not totally effective at treating relapsed aggressive lymphomas in patients who received CAR T therapy.
Treatment has shifted to immunotherapy, but survival gains have been small for people over age 75.
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets.
People treated with a durvalumab-based regimen before and after surgery had a 32% lower risk of disease recurrence or progression.
The Pragmatica-Lung Study, with fewer and simpler eligibility criteria, will test whether Cyramza plus Keytruda improves survival.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
Both Jemperli and Keytruda improved progression-free survival in late-stage clinical trials.
For people who are newly diagnosed or undergoing active treatment, there is little specific dietary guidance, but new evidence is emerging.
Combination therapy that includes a novel antibody is superior to immunotherapy alone for advanced non-small-cell lung cancer.
The checkpoint inhibitor is now approved for people with advanced non-small-cell lung cancer regardless of PD-L1 biomarker levels.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.